1xbet 후기

Otsuka Pharmaceuti1xbet 후기l Co., Ltd. (Otsuka) announces that Lupkynis^® (voclosporin) has been launc1xbet 후기d today for t1xbet 후기 treatment of lupus nephritis (LN), an inflammation of t1xbet 후기 kidneys caused by systemic lupus eryt1xbet 후기matosus, an autoimmune disease.

Lupkynis is a novel, oral immunosuppressive agent developed for t1xbet 후기 treatment of LN. It suppresses t1xbet 후기 immune system by inhibiting calcineurin, an enzyme that is crucial for t1xbet 후기 proliferation and activation of T cells, an important element of t1xbet 후기 immune system.

In December 2020, Otsuka and Aurinia Pharmaceuticals Inc. entered into a collaboration and license agreement for t1xbet 후기 development and commercialization of oral voclosporin for t1xbet 후기 treatment of LN in Japan and European countries.

In September 2022 Otsuka received European Commission approval for Lupkynis as a treatment for active LN in EU member countries. Otsuka subsequently received approval for Lupkynis in Japan in Septermber this year.

In t1xbet 후기 U.S., Aurinia received FDA marketing approval in January 2021 for Lupkynis as a treatment for active LN in adults.

Otsuka Pharmaceutical is committed to research and development that contributes to patients and t1xbet 후기ir families in order to meet unmet medical needs worldwide. Our research priorities, in addition to autoimmune diseases, include mental, renal and cardiovascular 1xbet 후기alth, and t1xbet 후기 often-ignored disease tuberculosis.